Maharashtra: FDA tells pharma body to regulate prices of cardiac stents

PTI Mumbai | Updated on January 23, 2018 Published on May 19, 2015


Charging the importers and distributors of cardiac stent of making over 100 per cent profit, Maharashtra’s Food and Drug Administration (FDA) today said it has asked the National Pharmaceutical Pricing Authority (NPPA) to regulate its “high prices“.

“It has come to FDA’s notice that demand for cardiac stents has increased considerably and also the fact that cardiac stents are being exorbitantly priced,” FDA Commissioner Harshadeep Kamble said here today.

“There were complaints from the public and also from non-governmental organisations (NGOs) regarding overpricing and overcharging of cardiac stents to needy patients,” the senior IAS official said.

Based on its inputs, Maharashtra FDA’s Vigilance Branch conducted a detailed probe against a major importing company dealing in cardiac stents.

The probe included investigation of six distributors and also involved seven hospitals in Mumbai, Pune and Nasik division, Kamble said.

The enquiry was conducted to know the cost to the importing company, also cost to the distributors, hospitals and cost to the patients vis-a-vis maximum retail price (MRP) of the cardiac stents, he said.

The study revealed that the MRP itself is exaggerated and to the tune of more than 300 to 700 per cent of the actual cost of importing cardiac stents by the importing company, Kamble said.

The profit margin earned by the importing company with respect to its distributors on an average is about 120 per cent and the average profit margin earned by distributors to the hospital is about 125 per cent, he said.

Published on May 19, 2015
This article is closed for comments.
Please Email the Editor